Hutman and Axela achieve milestone for rapid and cost effective pathogen screening

For this study, infected clinical samples were obtained from Hutman’s network of microbiology laboratory partners. Previously, rapid and sensitive detection of pathogens had been demonstrated using Axela’s bench top Ziplex platform. The new platform provided equal or superior results to the laboratory system but in a simple, cartridge format suitable for Point of Use applications. Having demonstrated this technical performance, Alena is now targeting initial product commercialization within 15-18 months.

The Alena value proposition is compelling whether compared to existing culture based or competitive nucleic acid detection systems. The Alena platform will be capable of multiplexing in excess of 100 pathogens on a single chip (see picture), including bacterial resistances to antibiotics and providing sample to answer results while the patient is still undergoing initial evaluation. Novel fluidics facilitate full automation in an inexpensive to manufacture consumable. The low capital cost of the instruments will allow Alena products to compete in broad infectious disease markets.

Initial applications include endocarditis, bone and joint infections, abscesses, meningitis and sepsis, as well as the detection of the most prevalent antibiotic resistances. The platform’s potential to provide rapid and cost effective pathogen screening in a near patient environment will represent a breakthrough in clinical protocols and patient outcome…. saving lives and reducing costs.

Hutman Diagnostics AG, founded in January 2011 and EN ISO 13485 certified since February 2015 is an in vitro diagnostics product development company, specialized on DNA based applications from patient samples, which the company collects through our extended network of microbiology laboratories.